{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:53:03Z","timestamp":1790617983099,"version":"4.1.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To analyze the short-term therapeutic efficacy of intravitreal injection of bevacizumab (IVB) for chronic central serous chorioretinopathy (CSC) according to the presence of choroidal neovascularization (CNV) using optical coherence tomography angiography (OCTA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective chart review was perfomed on cases of CSC with CNV (Group 1: n = 31) and an age-matched cases of CSC without CNV (Group 2: n = 30). The response to IVB was evaluated by changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), choroidal thickness (CT), and pachyvessel diameter. Univariate and multivariate linear regression analyses were performed to identify factors associated with the visual outcome of chronic CSC with CNV after IVB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, the CT values differed significantly between Groups 1 and 2 (371.55 \u00b1 67.09 vs. 417.33 \u00b1 71.32\n                      <jats:italic>\u03bc<\/jats:italic>\n                      m, p = 0.01). In Group 1, BCVA improved significantly (p &lt; 0.001), and CMT (p &lt; 0.001), CT (p = 0.001) and pachyvessel diameter (p = 0.045) decreased significantly, after IVB. In Group 2, only pachyvessel diameter (p = 0.001) was significantly smaller after IVB. Univariate analysis showed that the initial CT (B = 0.002, p = 0.026) and pachyvessel diameter (B = 0.002, p = 0.001) significantly affected visual outcome. In multivariate analysis, the initial pachyvessel diameter exhibited significant results (B = 0.002, p = 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IVB showed less effective short-term outcomes in chronic CSC patients without CNV than in patients with CNV. In chronic CSC with CNV, the short-term visual outcome after IVB was better in patients with a thinner choroid and smaller pachyvessels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0245342","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T17:10:16Z","timestamp":1610471416000},"page":"e0245342","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Short-term effect of anti-VEGF for chronic central serous chorioretinopathy according to the presence of choroidal neovascularization using optical coherence tomography angiography"],"prefix":"10.1371","volume":"16","author":[{"given":"Yong-Yeon","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa-Young","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Kook","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5614-077X","authenticated-orcid":true,"given":"Min-Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"issue":"2","key":"pone.0245342.ref001","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","article-title":"Central serous chorioretinopathy","volume":"86","author":"M Wang","year":"2008","journal-title":"Acta Ophthalmology"},{"issue":"3","key":"pone.0245342.ref002","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ajo.2009.11.017","article-title":"Central serous chorioretinopathy: A personal perspective","volume":"149","author":"LA Yannuzzi","year":"2010","journal-title":"American journal of ophthalmology"},{"issue":"6","key":"pone.0245342.ref003","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0161-6420(89)32810-7","article-title":"Long-term follow up of idiopathic central serous chorioretinopathy by fluorescein angiography","volume":"96","author":"R Levine","year":"1989","journal-title":"Ophthalmology"},{"issue":"5","key":"pone.0245342.ref004","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1006038621426","article-title":"Long-term follow-up of severe central serous chorioretinopathy using indocyanine green angiography","volume":"21","author":"K Shiraki","year":"1997","journal-title":"International Ophthalmology"},{"issue":"3","key":"pone.0245342.ref005","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/BF02175443","article-title":"Eight-year follow up of central serous chorioretinopathy with and without laser treatment","volume":"225","author":"R Brancato","year":"1987","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"4","key":"pone.0245342.ref006","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/eye.2017.293","article-title":"Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up","volume":"32","author":"A Arsan","year":"2018","journal-title":"Eye"},{"issue":"9","key":"pone.0245342.ref007","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/IAE.0b013e3182680a66","article-title":"Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration","volume":"32","author":"AT Fung","year":"2012","journal-title":"Retina"},{"issue":"2","key":"pone.0245342.ref008","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/eye.2008.55","article-title":"Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy","volume":"23","author":"WC Huang","year":"2009","journal-title":"Eye"},{"issue":"1","key":"pone.0245342.ref009","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000314709","article-title":"Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy","volume":"225","author":"M Inoue","year":"2011","journal-title":"Ophthalmologica"},{"issue":"4","key":"pone.0245342.ref010","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/112067210901900415","article-title":"Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy","volume":"19","author":"KB Schaal","year":"2009","journal-title":"European Journal of Ophthalmology"},{"issue":"6","key":"pone.0245342.ref011","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ajo.2007.02.039","article-title":"Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin","volume":"143","author":"WM Chan","year":"2007","journal-title":"American journal of ophthalmology"},{"key":"pone.0245342.ref012","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000442775","article-title":"Optical coherence tomography angiography in healthy subjects","volume":"56","author":"G Coscas","year":"2016","journal-title":"Developments in Ophthalmology"},{"issue":"5","key":"pone.0245342.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","article-title":"Optical coherence tomography angiography","volume":"64","author":"RF Spaide","year":"2018","journal-title":"Progress in Retinal and Eye Research"},{"issue":"8","key":"pone.0245342.ref014","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jamaophthalmol.2015.1320","article-title":"Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography","volume":"133","author":"MA Bonini Filho","year":"2015","journal-title":"JAMA Ophthalmology"},{"issue":"1","key":"pone.0245342.ref015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","article-title":"Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy","volume":"22","author":"RH Loo","year":"2002","journal-title":"Retina"},{"issue":"8","key":"pone.0245342.ref016","first-page":"1581","volume":"257","author":"F Sulzbacher","year":"2019","journal-title":"Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA) Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"6","key":"pone.0245342.ref017","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ajo.2015.08.028","article-title":"Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease","volume":"160","author":"KK Dansingani","year":"2015","journal-title":"American journal of ophthalmology"},{"issue":"3","key":"pone.0245342.ref018","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ajo.2015.06.016","article-title":"Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography","volume":"160","author":"M Quaranta-El Maftouhi","year":"2015","journal-title":"American journal of ophthalmology"},{"issue":"2","key":"pone.0245342.ref019","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3928\/23258160-20160126-05","article-title":"Vascularization of irregular retinal pigment epithelial detachments in chronic central serous chorioretinopathy evaluated with OCT angiography","volume":"47","author":"TE de Carlo","year":"2016","journal-title":"Ophthalmic Surgery, Lasers & Imaging Retina"},{"issue":"3","key":"pone.0245342.ref020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/IAE.0000000000001580","article-title":"Optical coherence tomography angiography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy","volume":"38","author":"E Bousquet","year":"2018","journal-title":"Retina"},{"issue":"4","key":"pone.0245342.ref021","first-page":"1","article-title":"The incidence of neovascularization in central serous chorioretinopathy by optical coherence tomography angiography","volume":"00","author":"MC Savastano","year":"2020","journal-title":"Retina."},{"issue":"1","key":"pone.0245342.ref022","doi-asserted-by":"crossref","first-page":"11389","DOI":"10.1038\/s41598-019-47738-9","article-title":"Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy","volume":"9","author":"N Nagai","year":"2019","journal-title":"Scientific Reports"},{"issue":"2","key":"pone.0245342.ref023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10384-020-00722-7","article-title":"One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions","volume":"64","author":"H Matsumoto","year":"2020","journal-title":"Japanese Journal of Ophthalmology"},{"issue":"2","key":"pone.0245342.ref024","doi-asserted-by":"crossref","first-page":"e0229134","DOI":"10.1371\/journal.pone.0229134","article-title":"Comparison of choroidal thickness measurements using swept source and spectral domain optical coherence tomography in pachychoroid diseases","volume":"15","author":"MW Lee","year":"2020","journal-title":"PLoS One."},{"issue":"2","key":"pone.0245342.ref025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","article-title":"Central serous chorioretinopathy: update on pathophysiology and treatment","volume":"58","author":"B Nicholson","year":"2013","journal-title":"Survey of Ophthalmology"},{"issue":"4","key":"pone.0245342.ref026","doi-asserted-by":"crossref","first-page":"503","DOI":"10.5301\/EJO.2011.6290","article-title":"Ruiz-Moreno JM, Fernandez-Mu\u00f1oz M. Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy","volume":"21","author":"Q. Montero JA","year":"2011","journal-title":"European Journal of Ophthalmology"},{"issue":"5","key":"pone.0245342.ref027","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00417-020-04623-w","article-title":"Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents","volume":"258","author":"B Schworm","year":"2020","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"2","key":"pone.0245342.ref028","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s10384-018-0562-0","article-title":"Efficacy of treat\u2011and\u2011extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age\u2011related macular degeneration","volume":"62","author":"H Matsumoto","year":"2018","journal-title":"Japanese journal of Ophthalmology"},{"issue":"8","key":"pone.0245342.ref029","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1097\/IAE.0000000000001744","article-title":"Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: Twelve-Month results of the Minerva study","volume":"38","author":"TYY Lai","year":"2018","journal-title":"Retina"},{"issue":"12","key":"pone.0245342.ref030","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00417-018-4143-1","article-title":"Morphologic features of large choroidal vessel layer: age-related macular degeneration, polypoidal choroidal vasculopathy, and central serous chorioretinopathy","volume":"256","author":"J Baek","year":"2018","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"4","key":"pone.0245342.ref031","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/ceo.13438","article-title":"Choroidal morphology under pachydrusen","volume":"47","author":"J Baek","year":"2019","journal-title":"Clinical & experimental Ophthalmology"},{"issue":"3","key":"pone.0245342.ref032","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/IAE.0000000000000742","article-title":"En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography","volume":"36","author":"KK Dansingani","year":"2016","journal-title":"Retina"},{"issue":"2","key":"pone.0245342.ref033","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1167\/iovs.17-22144","article-title":"Changes in choroidal thickness after intravitreal injection of anti\u2011vascular endothelial growth factorin pachychoroid neovasculopathy","volume":"59","author":"N Padr\u00f3n\u2011P\u00e9rez","year":"2018","journal-title":"Investigative ophthalmology & visual science"},{"key":"pone.0245342.ref034","first-page":"8125267","article-title":"Choriocapillaris Loss in Advanced Age-Related Macular Degeneration","volume":"30","author":"CA Moreira-Neto","year":"2018","journal-title":"Journal of Ophthalmology"},{"issue":"12","key":"pone.0245342.ref035","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/eye.2013.236","article-title":"Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review","volume":"27","author":"YR Chung","year":"2013","journal-title":"Eye"},{"issue":"1","key":"pone.0245342.ref036","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/IAE.0000000000001917","article-title":"Twelve-month efficacy of intravitreal bevacizumab injection for chronic, atypical, or recurrent central serous chorioretinopathy","volume":"39","author":"YR Chung","year":"2019","journal-title":"Retina"},{"issue":"6","key":"pone.0245342.ref037","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/eye.2015.58","article-title":"Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients","volume":"29","author":"GA Kim","year":"2015","journal-title":"Eye"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T17:11:15Z","timestamp":1610471475000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245342"}},"subtitle":[],"editor":[{"given":"Alon","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0245342","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]}}}